

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Erik Buntinx
Serial No. : 10/752,423
Filed : January 6, 2004
For : METHOD OF TREATING MENTAL DISORDERS USING D4
AND 5-HT2A ANTAGONISTS, INVERSE AGONISTS OR
PARTIAL AGONISTS
Art Unit : 1627
Examiner : Umamaheswari Ramachandran
Customer No. : 1912
Confirmation No.: 3783

COMMUNICATION TO SUBMIT TERMINAL DISCLAIMER

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This Communication is submitted in response to telephonic communications between Examiner Umamaheswari Ramachandran and Alan D. Miller regarding obviousness-type double patenting between the claims of the above-identified patent application and claims of earlier-filed patent family member, U.S. Patent Application No. 10/725,965, filed on December 2, 2003.

EFS
Confirmation No. 3783
Applicant: Erik Buntinx
Serial No.: 10/752,423
Filed: January 6, 2004
July 27, 2010 Communication to Submit Terminal Disclaimer
page 2 of 2

Applicant attaches hereto a Terminal Disclaimer in compliance with 37 C.F.R. §1.321(c) to remove a double patenting rejection over U.S. Patent Application No. 10/725,965.

A fee of \$70.00 is required for a small entity for submitting a Terminal Disclaimer. Authorization is hereby given to charge the \$70.00 fee for submitting the Terminal Disclaimer to Deposit Account No. 01-1785. No additional fee is deemed necessary in connection with the submission of this Communication. However, if any other fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 01-1785.

Respectfully submitted,

AMSTER, ROTHSTEIN & EBENSTEIN LLP
Attorneys for Applicants
90 Park Avenue
New York, New York 10016
(212) 336-8000

Dated: July 27, 2010
New York, New York

By: /Alan D. Miller/
Alan D. Miller, Reg. No. 42,889